Gastroenterology and Inflammatory Bowel Disease
Xencor Inc. supports clinical research in ulcerative colitis, with interest in therapies aimed at reducing colonic and rectal inflammation and improving disease control in moderately to severely active disease.
- Ulcerative colitis
- Clinical remission
- Gastrointestinal inflammation
The sponsor’s work in this area reflects a focus on immune-mediated disorders of the bowel and treatments intended to restore intestinal function.
Thoracic Oncology
The company funds studies in advanced non-small cell lung cancer, including research on treatment combinations for patients with advanced lung malignancy.
- Non-small cell lung cancer
- Advanced lung cancer
- Combination therapy
This area includes clinical evaluation of immuno-oncology approaches alongside established anticancer regimens.
Solid Tumor Oncology
Xencor Inc. is active in research on advanced solid tumors, with attention to treatment development for difficult-to-manage metastatic and refractory cancers.
- Advanced solid tumors
- Investigational cancer therapies
- Refractory malignancies
Its oncology portfolio extends across multiple tumor types, supporting therapeutic development in broadly defined advanced cancer settings.
Renal Cell Carcinoma
The sponsor also funds studies in clear cell renal cell carcinoma, focusing on treatment options for advanced kidney cancer.
- Clear cell renal cell carcinoma
- Advanced kidney cancer
- Oncology immunotherapy
This research area addresses a distinct genitourinary cancer population with unmet therapeutic need.
